ArticleNews reportPHN-04932026-10-30 16:37 CT
This Week at FDA: New ConOps for drug inspections, AI policy proposal, and more
Source · RAPS
TLDR
RAPS reports that HHS Secretary Robert Kennedy Jr.’s new enforcement discretion policy on compounding six unapproved peptides may face state resistance. Citing Politico, the article notes that states are not obligated to follow the policy, which was announced this week.
01—Key points
- 01The excerpt does not identify the six peptides covered by the policy.
- 02A Texas compounding pharmacy owner told Politico that the initial rollout could be uncertain.
- 03The broader roundup also covers revised FDA drug-inspection coordination and proposed AI oversight legislation.
Why it matters Editorial
States’ discretion over whether to follow the policy could lead to differences in its implementation for peptide compounding.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.